Talphera, Inc.
TLPHTalphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for use in medically supervised settings, particularly hospitals and intensive care units.
Earnings
Next report
Date not yet announcedFinancials
Q3 2026Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
Profile
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for use in medically supervised settings, particularly hospitals and intensive care units. The company's primary value proposition centers on its lead product candidate, Niyad, which is designed to provide regional anticoagulation for patients undergoing continuous renal replacement therapy. Talphera aims to address unmet needs in acute care by offering alternatives to systemic anticoagulants that carry high bleeding risks.
Talphera is a clinical-stage developer seeking to establish a first-mover advantage with the first FDA-approved regional anticoagulant for CRRT. It competes by targeting a significant portion of the market that currently uses no anticoagulation due to safety concerns with existing systemic options.
FAQ
- What is Talphera, Inc.'s market cap?
- Talphera, Inc. (TLPH) has a market capitalization of $56.6M and trades on NASDAQ.
- Who are Talphera, Inc.'s competitors?
- Talphera, Inc.'s key competitors include Baxter International Inc., Milestone Pharmaceuticals Inc. Common Shares, Amphastar Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
- Who does Talphera, Inc. partner with?
- Talphera, Inc.'s notable partners include Alora Pharmaceuticals, LLC, XOMA (US) LLC, Laboratoire Aguettant.
- What subsidiaries does Talphera, Inc. have?
- Talphera, Inc.'s subsidiaries include Lowell Therapeutics, Inc..
- Where is Talphera, Inc. headquartered?
- Talphera, Inc. is headquartered in United States of America and employs approximately 15 people. It has been publicly traded since 2011.